Loading...
•
Jun 30, 2024
Personalis Q2 2024 Earnings Report
Personalis' Q2 2024 financial results were reported, featuring strong revenue growth.
Key Takeaways
Personalis reported a 35% year-over-year increase in total company revenue, driven by a 117% increase in revenue from biopharma business. The company also delivered 561 total molecular tests, a 66% increase compared to the prior quarter. They raised the full year revenue guidance for 2024.
Total company revenue increased by 35% year-over-year, reaching $22.6 million.
Revenue from pharma testing and services grew by 117% year-over-year, totaling $13.2 million.
Net loss decreased by 47% year-over-year, amounting to $12.8 million.
Delivered 561 total molecular tests, a 66% increase compared with the prior quarter.
Revenue by Segment
Forward Guidance
Personalis provided guidance for the third quarter and revised full year 2024 outlook.
Positive Outlook
- Total company revenue is expected to be in the range of $21.0 to $22.0 million for Q3 2024.
- Revenue from pharma tests, enterprise sales, and other customers is expected to be in the range of $17.0 to $18.0 million for Q3 2024.
- Revenue from population sequencing is expected to be approximately $4.0 million for Q3 2024.
- Total company revenue is expected to be in the range of $79.0 to $81.0 million for the full year 2024, increased from $76.0 to $78.0 million.
- Revenue from pharma tests, enterprise sales, and all other customers is expected to be in the range of $71.0 to $73.0 million for the full year 2024, increased from prior guidance of $68.0 to $70.0 million.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...